Jones Day - MSQ Global Biopharma Networking Reception in Munich

 

On November 6th, 2023 the Global Biopharma Networking Reception was co-hosted by Jones Day and MSQ Ventures with supporting organizations BioCentury, BayHelix, BioAroundWorld, and our co-sponsor MC Services. The event served as a platform for the industry's leading minds to showcase their innovative contributions, paving the way for the future of healthcare and biotechnology. 

The event highlighted company presentations showcasing their unique contributions to the field, offering a glimpse into the future of healthcare and biotech.  

Neurimmune AG is a biotech company that uses human immune memory to develop antibody-based therapies. Neurimmune scientists, along with researchers at the University of Zurich, discovered aducanumab, an antibody for the treatment of Alzheimer's disease. Neurimmune licensed aducanumab to Biogen, which is developing the drug in collaboration with Neurimmune. In 2021, the US FDA approved aducanumab for the treatment of Alzheimer's disease. Neurimmune is also developing antibodies for the treatment of amyotrophic lateral sclerosis (ALS) and transthyretin amyloid cardiomyopathy (ATTR-CM) in early clinical development. In addition to antibodies, they are also developing other types of therapies, including small molecules that activate M1 AChRs and gene therapies based on vectorized human antibodies. 

Regend Therapeutics is a company that wants to revolutionize medicine with cell therapy technology. They are leading the way in the development of regenerative medicine, which has the potential to restart lives. Regend is committed to innovation, and they are driven by the needs of patients and the latest scientific research. They are constantly coming up with new and creative scientific ideas, and they are rigorous in their evaluation of new treatments. 

Oryx GmbH & Co. KG is a biotech company that bridges the gap between academic cancer research and the pharmaceutical industry. They develop early-stage cancer research projects to clinical proof of concept, before partnering with pharmaceutical companies to complete the final development and marketing. Oryx's goal is to create maximum value for patients and investors by developing innovative and effective cancer treatments. 

Erasca Inc. believe that to effectively shut down a pathway that signals as promiscuously as RAS/MAPK, a holistic approach must be taken to target not just individual nodes, but multiple nodes and cooperative mechanisms in parallel. Consequently, we are pursuing three therapeutic strategies that may be used in combination to comprehensively, and perhaps synergistically, shut down the RAS/MAPK pathway. 

Erasca Inc. vision is to one day erase cancer1 in at least 100,000 patients annually as a leading global oncology company. 

Hangzhou Yirui Pharmaceutical Technology Co., Ltd has consolidated alliances with universities, research centers, production and marketing facilities, drug chain management, and drug sales platforms. Each partnership continues to bring us closer toward our mission and turn our strategic vision into realities. In addition to our own research and development, we are continuously looking for valuable collaboration with pharmaceutical companies worldwide that allow us to strengthen our portfolio and pipeline, to share our values and to help more patients in timely manner. If you believe that your work and product would support YIRUI to achieve the goal, please reach out to us. 

Nutshell Therapeutics is leveraging its cutting-edge technology based on protein dynamics, Nutshell is fostering a new era of drug discovery, Nutshels AlloStar allosteric drug discovery platform, composed of a powerful and well-integrated set of computational modules and experimental tools based on our proprietary AI algorithm and deep know-how derived from biochemistry and biophysics, possesses the unique capability to discover a host of drug entities including various types of protein activators, subtype/mutation selective small molecules, regulatory molecules of protein-protein interaction (PPI) and stabilizer of intrinsically disordered proteins (IDPs), thus opening up an unprecedented new horizon for small molecule innovation. 

AneuroTech is developing its late-stage Phase III drug ANT01 in Partial Responsive Depression (PRD). ANT01 is a once-daily, orally-administered small molecule to attack Subjective Cognitive Decline and Potentiate Initial Antidepressant Therapies. 

Secarna Pharmaceuticals GmbH & Co. KG is a leading independent European antisense drug discovery company with multiple best-in-class antisense therapies in various stages of pre-clinical development addressing high unmet medical needs across several therapeutic areas.  

Secarna Pharmaceuticals aims to leverage our proprietary ASO discovery platform, LNAplus™, to bring novel, highly specific, safe, and efficacious ASO therapies addressing a variety of targets deemed undruggable by current approaches to patients in need. 

invIOs GmbH is developing NEXT-GENERATION CANCER THERAPEUTICS that empower and educate the immune system to fight cancer. invIOs leverage their DEEP EXPERTISE IN IMMUNE-SYSTEM ACTIVATION to advance a focused pipeline of individualized and targeted approaches against solid tumors 

Atriva Therapeutics is a biopharmaceutical company pioneering the development of first-in-class host-cell-targeting antiviral and immunomodulatory therapies. The company was set up by a team of leading scientists in viral disease research and industry experts with a proven track record. Atriva aims to develop novel, highly efficacious, and safe therapies for the treatment of severe diseases caused by RNA-viruses with a high unmet medical need and huge cost burden to healthcare systems around the world such as influenza virus, respiratory syncytial virus infections, dengue fever, and hanta virus infections. 

AATec Medical GmbH is a biotech company developing a product platform based on recombinant alpha-1 antitrypsin (AAT) for the treatment of inflammatory diseases, virus infections, and rare diseases. We have successfully demonstrated proof-of-principle in several indications and are preparing for a proof-of-concept clinical trial with inhaled AAT in respiratory applications. 

AATec Medical is developing a product platform based on recombinant alpha-1 antitrypsin (AAT) for the treatment of increasing respiratory diseases. AATec Medical lead product candidate ATL-105 is an inhalation treatment for ARDS, respiratory virus infections, and allergic asthma. 

As we reflect on the Global Biopharma Networking Reception of 2023, the unwavering commitment for emerging biopharma to improving patient health, pushing scientific boundaries, and collaborating with like-minded organizations resonates with the core values of progress and compassion. The profound impact they aim to make on the world is both inspiring and promising, leaving us with a sense of hope and anticipation for the groundbreaking advancements that lie ahead. We extend our heartfelt gratitude to all participants and sponsors for their invaluable contributions to this remarkable event. Together, we continue to march forward in our collective quest to transform and enhance the world of biopharma.